

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6195264

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIOThERA, INC.	06/09/2020
RECEIVING PARTY DATA	
Name:	HIBERCELL, INC.
Street Address:	619 WEST 54TH STREET
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10019
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	10111900
Application Number:	16174157
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	US-PatentBos@goodwinlaw.com, dgrimes@goodwinlaw.com
Correspondent Name:	GOODWIN PROCTER LLP
Address Line 1:	100 NORTHERN AVENUE
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	HBC-024C1
NAME OF SUBMITTER:	CATHERINE M. MCCARTY
SIGNATURE:	/Catherine M. McCarty/
DATE SIGNED:	07/10/2020
Total Attachments: 13	
source=HBC-Executed Assignment#page1.tif	
source=HBC-Executed Assignment#page2.tif	
source=HBC-Executed Assignment#page3.tif	
source=HBC-Executed Assignment#page4.tif	
source=HBC-Executed Assignment#page5.tif	
source=HBC-Executed Assignment#page6.tif	

source=HBC-Executed Assignment#page7.tif
source=HBC-Executed Assignment#page8.tif
source=HBC-Executed Assignment#page9.tif
source=HBC-Executed Assignment#page10.tif
source=HBC-Executed Assignment#page11.tif
source=HBC-Executed Assignment#page12.tif
source=HBC-Executed Assignment#page13.tif

PATENT RIGHTS ASSIGNMENT

This Patent Rights Assignment (this "Assignment") is made effective this 17th day of June, 2020, by and between **Biothera, Inc.**, a corporation organized and existing under the laws of Delaware, and having a usual place of business at 2825 Fairview Ave N., Roseville, MN 55123 ("Assignor") and **Hibercell, Inc.**, a corporation organized and existing under the laws of Delaware, and having a usual place of business at 619 West 54th Street, New York, New York 10019 ("Assignee").

WHEREAS, Assignor possesses certain rights in and to the patents and patent applications (and patents issuing on such applications) set forth on Exhibit A attached hereto and incorporated herein by reference (collectively, the "Patent Rights") and the invention(s) described and/or claimed in the Patent Rights (the "Inventions"); and

WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated as of May 15, 2020 (the "Purchase Agreement"), pursuant to which Assignor agreed to transfer, sell and convey to Assignee certain of the assets of Assignor, including the Inventions and Patent Rights;

WHEREAS, Assignor now wishes to assign the Inventions and Patent Rights to Assignee, and Assignee desires to acquire the Inventions and Patent Rights from Assignor; and

WHEREAS, the execution and delivery of this Assignment is a condition to Closing under the Purchase Agreement.

NOW, THEREFORE, in consideration of the premises set forth above and in the Purchase Agreement and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged:

Assignor does hereby sell, assign, convey and transfer unto Assignee and its successors, assigns, and legal representatives, Assignor's entire right, title and interest in and throughout the world in and to the Inventions, together with Assignor's entire right, title and interest in and to the Patent Rights and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, reviews, extensions, and substitutions of patents and patent applications within the Patent Rights or such other patents, and any right, title and interest Assignor may have in applications to which the Patent Rights claim priority; the Inventions and the Patent Rights to be held and enjoyed by Assignee for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made; and Assignor hereby conveys all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment. Assignor hereby acknowledges that this assignment, being of Assignor's entire right, title and interest in and to the Inventions and the Patent Rights carries with it the right in Assignee to apply for and obtain from competent authorities in all countries of the world any and all patents for the Patent Rights and Inventions by attorneys and agents of Assignee's selection and the right to procure the grant of all patents for the Patent Rights and Inventions to Assignee in its own name as assignee of Assignor's entire right, title and interest therein.

Assignor does hereby authorize the Director of the United States Patent & Trademark Office, and the empowered officials of all other governments whose duty it is to record patents, applications and title thereto, to record the Patent Rights and title thereto as the property of Assignee, its successors, assigns, or legal representatives in accordance with the terms of this instrument.

Assignor does hereby further authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Patent Rights or patents as shall be granted upon the Patent Rights, or applications based thereon, to Assignee, its successors, assigns, or legal representatives.

Assignee and Assignor also agree that multiple copies of this Assignment may be executed, each of which shall be deemed an original, and each of which shall be valid and binding upon Assignee and Assignor. The copies may be delivered via facsimile, electronic mail or other transmission method and any copy so delivered shall be deemed to have been duly and validly executed and delivered and be valid and effective for all purposes.


[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the date first written above.

ASSIGNOR: Biothera, Inc.
Name: Richard Mueller


Signature: 
Title: Chief Executive Officer

On this 9th day of June, 2020, before me, the undersigned Notary Public, personally appeared Richard Mueller proved to me through satisfactory evidence of identification, which was/were Driver's License to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignor and executed this document of his/her own free will.


Signature of Notary

(Seal)


My Commission Expires: Jan 31, 2024



[Signature Page to IR Seller Patent Rights Assignment]

PATENT
REEL: 053177 FRAME: 0433

ASSIGNEE: HiberCell, Inc.
Name: Alan C. Rigby, PhD

Signature: 
Title: _____
President & Chief Executive
Officer

On this ____ day of _____, 2020, before me, the undersigned Notary Public, personally appeared _____, proved to me through satisfactory evidence of identification, which was/were _____, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignee and executed this document of his/her own free will.

(Seal)

Signature of Notary

My Commission Expires: _____

Exhibit A**PATENT RIGHTS**

Owner	Title	Country	Patent /Application No.	Filing date	Status
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT	United States	16/068,868	7/9/18	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT	Europe	17736531.9	7/9/18	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT	United States	10,111,901	12/21/16	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT	United States	16/174,177	10/29/18	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT	China	201580049292.0	7/10/15	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT	Europe	15818863.1	7/10/15	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT	Japan	2017-522465	1/7/17	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT	United States	10,111,900	12/21/16	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT	United States	16/174,157	10/29/18	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT	China	201580072494.7	11/5/15	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT	Europe	15856595.2	11/5/15	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT	Japan	2017-524481	11/5/15	Pending

	AFFECT THE TUMOR MICROENVIRONMENT				
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	United States	10,272,101	2/21/17	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	United States	9,610,303	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Australia	2007258191	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Australia	2014201427	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Canada	2,655,414	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	China	200780029944.X	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	China	201310718360.0	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Italy	2032180	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Spain	2032180	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	France	2032180	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	United Kingdom	2032180	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Germany	2032180	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Ireland	2032180	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Hong Kong	HK1138215	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Israel	195937	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Israel	236842	1/21/15	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Japan	6196280	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Japan	5851472	6/15/07	Granted

Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Mexico	297088	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Russia	2490279	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	GLUCAN PREPARATIONS	Singapore	148584	6/15/07	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	YEAST CELL WALL ENRICHED IN MANNAN OLIGOSACCHARIDE PROTEIN	United States	10,582,723	15/4/15	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	YEAST CELL WALL ENRICHED IN MANNAN OLIGOSACCHARIDE PROTEIN	Europe	15780227.3	15/4/15	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	YEAST CELL WALL ENRICHED IN MANNAN OLIGOSACCHARIDE PROTEIN	Brazil	11 2016 023672 6	15/4/15	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	YEAST CELL WALL ENRICHED IN MANNAN OLIGOSACCHARIDE PROTEIN	Canada	2,945,793	15/4/15	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	YEAST CELL WALL ENRICHED IN MANNAN OLIGOSACCHARIDE PROTEIN	Mexico	MX/a/2016/013473	15/4/15	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	United States	7,981,447	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	United States	8,530,642	11/7/11	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	United States	8,859,759	24/4/13	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Brazil	PI 0811274-6	8/5/08	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Canada	2,690,918	8/12/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Australia	2008251847	7/1/10	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	China	200880014957.4	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	China	201510666215.1	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Europe	8754267.6	8/5/08	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Indonesia	W-00200903453	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Japan	2010-507462	8/5/08	Granted

Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Japan	2014-120772	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	South Korea	10-2009-7025513	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	South Korea	10-2014-7023009	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Malaysia	PI 20094702	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Mexico	MX/a/2011/008055	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PARTICULATE-SOLUBLE GLUCAN PREPARATION	Mexico	MX/a/2009/012070	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	PROCESS FOR PRODUCING A SOLUBLE β -GLUCAN	Ukraine	200912721	8/5/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS	United States	9,943,607	5/9/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	United States	14/398,019	3/14/13	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	Australia	2013257139	11/5/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	Australia	2018203444	5/15/18	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	Canada	2,872,009	10/29/14	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	China	201380034978.3	12/30/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	France	2844262	3/14/13	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	Germany	2844262	3/14/13	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	Ireland	2844262	3/14/13	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	Italy	2844262	11/18/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	Spain	2844262	3/14/13	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β -GLUCAN IMMUNOTHERAPEUTIC METHODS	United Kingdom	2844262	3/14/13	Granted

Biothera, Inc. (dba Immuno Research, Inc.)	β-GLUCAN IMMUNOTHERAPEUTIC METHODS	Japan	6416751	3/14/13	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	β-GLUCAN IMMUNOTHERAPEUTIC METHODS	South Korea	10-2014-7033316	11/26/14	Allowed
Biothera, Inc. (dba Immuno Research, Inc.)	β-GLUCAN IMMUNOTHERAPEUTIC METHODS	Russia	2643331	11/28/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	United States	9,885,726	6/2/16	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	United States	10,114,027	12/18/17	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	Australia	2014357446	5/30/16	Allowed
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	Canada	2,932,192	12/1/14	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	Europe	14868177.8	12/1/14	Allowed
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	Japan	2016-536615	12/1/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	Mexico	MX/a/2016/007148	6/1/16	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	New Zealand	720608	5/30/16	Pending
Biothera, Inc. (dba Immuno Research, Inc.)	BETA-GLUCAN ASSAY METHODS	Singapore	11201604418W	12/1/14	Granted
University of Louisville Research Foundation	CANCER THERAPY USING BETA GLUCAN AND ANTIBODIES	United States	8,883,760	9/4/02	Granted
University of Louisville Research Foundation	CANCER THERAPY USING BETA GLUCAN AND ANTIBODIES	United States	9,522,187	10/30/14	Granted
University of Louisville Research Foundation	CANCER THERAPY USING BETA GLUCAN AND ANTIBODIES	Canada	2,496,508	9/4/02	Granted
University of Louisville Research Foundation	CANCER THERAPY USING BETA GLUCAN AND ANTIBODIES	China	ZL 0382 4 893	9/4/02	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	United States	10,092,646	10/30/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Australia	2013257141	11/6/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Canada	2,872,010	10/29/14	Pending

Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	China	ZL201380034980.0	12/30/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Germany	2854530	11/28/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Spain	2854530	11/28/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	France	2854530	11/28/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	United Kingdom	2854530	11/28/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Ireland	2854530	11/28/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Italy	2854530	11/28/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Japan	6272305	10/30/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY	Russia	2629334	11/28/14	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	United States	9,694,070	7/9/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	United States	10,166,289	5/31/17	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	France	2753337	7/9/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	Germany	2753337	7/9/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	Ireland	2753337	7/9/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	Italy	2753337	7/9/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	Spain	2753337	7/9/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE	United Kingdom	2753337	7/9/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	OPSONIZED β -GLUCAN PREPARATIONS AND METHODS	United States	10,092,657	6/1/12	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	OPSONIZED β -GLUCAN PREPARATIONS AND METHODS	Europe	12793220	6/1/12	Allowed

Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Australia	2008305545	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Canada	2,700,922	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	China	201510514507.3	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	China	201110225696.4	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	United Kingdom	8833584.9	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	France	8833584.9	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Germany	8833584.9	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Italy	8833584.9	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Netherlands	8833584.9	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Spain	8833584.9	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Finland	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	France	3072518	29/9/08	Granted

	PSYCHOLOGICAL WELL-BEING				
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Germany	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Ireland	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Italy	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Netherlands	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Norway	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Poland	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Romania	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Spain	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Sweden	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Switzerland	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Turkey	3072518	29/9/08	Granted

Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	United Kingdom	3072518	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Hong Kong	12106829.0	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Japan	2015-111978	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Malaysia	PI 2010001341	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Mexico	MX/a/2010/003462	29/9/08	Granted
Biothera, Inc. (dba Immuno Research, Inc.)	THE USE OF β -GLUCAN ON UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING	Philippines	10-2010-500664	29/9/08	Granted